205 related articles for article (PubMed ID: 8788772)
21. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Bonneterre J
Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
23. New cytotoxic drugs in clinical development.
Extra JM; Rousseau F; Culine S; Giacchetti S; Madelaine I; Marty M
Nouv Rev Fr Hematol (1978); 1991; 33(6):451-6. PubMed ID: 1687829
[No Abstract] [Full Text] [Related]
24. [Current status of camptothecin derivatives as natural antitumor agents].
Pan XD; Wang CY
Yao Xue Xue Bao; 2003 Sep; 38(9):715-20. PubMed ID: 14730926
[No Abstract] [Full Text] [Related]
25. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
26. Promising new agents in oncologic treatment.
Mani S; Ratain MJ
Curr Opin Oncol; 1996 Nov; 8(6):525-34. PubMed ID: 8971473
[TBL] [Abstract][Full Text] [Related]
27. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
Cho LC; Choy H
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):29-39. PubMed ID: 15255165
[TBL] [Abstract][Full Text] [Related]
29. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
30. Clinical use of topoisomerase I inhibitors in anticancer treatment.
Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
[TBL] [Abstract][Full Text] [Related]
31. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
[No Abstract] [Full Text] [Related]
32. Topoisomerase I inhibitors in the treatment of head and neck cancer.
Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
[TBL] [Abstract][Full Text] [Related]
33. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
34. Factors affecting topotecan sensitivity in human leukemia samples.
Kaufmann SH; Gore SD; Letendre L; Svingen PA; Kottke T; Buckwalter CA; Jones RJ; Grochow LB; Burke PJ; Donehower RC; Rowinsky EK
Ann N Y Acad Sci; 1996 Dec; 803():128-42. PubMed ID: 8993506
[No Abstract] [Full Text] [Related]
35. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
36. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
Besterman JM
Ann N Y Acad Sci; 1996 Dec; 803():202-9. PubMed ID: 8993513
[TBL] [Abstract][Full Text] [Related]
37. New chemotherapeutic agents in non-small-cell lung cancer.
Feigal EG; Christian M; Cheson B; Grever M; Friedman MA
Semin Oncol; 1993 Apr; 20(2):185-201. PubMed ID: 7683142
[No Abstract] [Full Text] [Related]
38. Camptothecins: a review of their chemotherapeutic potential.
Ulukan H; Swaan PW
Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan (CPT-11): pharmacology and clinical applications.
Masuda N; Kudoh S; Fukuoka M
Crit Rev Oncol Hematol; 1996 Sep; 24(1):3-26. PubMed ID: 8869796
[No Abstract] [Full Text] [Related]
40. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
